H2 阻滞剂法莫替丁可抑制小鼠模型后纵韧带骨化的进展。
The H2 blocker famotidine suppresses progression of ossification of the posterior longitudinal ligament in a mouse model.
机构信息
Department of Sensory and Motor System Medicine, The University of Tokyo Graduate School of Medicine, Tokyo , Japan ; Division of Clinical Biotechnology , The University of Tokyo Graduate School of Medicine , Tokyo , Japan.
Division of Clinical Biotechnology , The University of Tokyo Graduate School of Medicine , Tokyo , Japan.
出版信息
RMD Open. 2015 May 14;1(1):e000068. doi: 10.1136/rmdopen-2015-000068. eCollection 2015.
BACKGROUND
Ossification of the posterior longitudinal ligament (OPLL) of the spine is a common human myelopathy that leads to spinal cord compression. No disease-modifying drug for OPLL has been identified, whereas surgery and conservative management have been established.
OBJECTIVES
To evaluate the therapeutic potential of the H2 blocker famotidine for ectopic ossification in the cervical spine in an OPLL mouse model.
METHODS
The H2 blocker famotidine was orally administered to Enpp1 (ttw/ttw) mice, a model of OPLL, at either 4 or 15 weeks of age. Radiological and survival rate analyses were performed to assess the effects of famotidine on OPLL-like lesions and mortality in Enpp1 (ttw/ttw) mice.
RESULTS
Oral administration of famotidine suppressed the progression of OPLL-like ectopic ossification and reduced mortality in Enpp1 (ttw/ttw) mice when administration began at 4 weeks of age, early in the development of ossification.
CONCLUSIONS
This study points to the use of famotidine as a disease-modifying drug for ectopic ossification of spinal soft tissue, including OPLL.
背景
脊柱后纵韧带骨化症（OPLL）是一种常见的人类脊髓病，可导致脊髓受压。目前尚未发现针对 OPLL 的疾病修饰药物，而手术和保守治疗已经确立。
目的
在 OPLL 小鼠模型中评估 H2 受体阻滞剂法莫替丁治疗颈椎异位骨化的治疗潜力。
方法
在 Enpp1（ttw/ttw）小鼠（OPLL 模型）4 或 15 周龄时，经口给予 H2 受体阻滞剂法莫替丁。进行影像学和存活率分析，以评估法莫替丁对 Enpp1（ttw/ttw）小鼠中 OPLL 样病变和死亡率的影响。
结果
当在骨化早期的 4 周龄时开始给药时，法莫替丁可抑制 Enpp1（ttw/ttw）小鼠中 OPLL 样异位骨化的进展并降低其死亡率。
结论
这项研究表明，法莫替丁可作为一种用于治疗包括 OPLL 在内的脊柱软组织异位骨化的疾病修饰药物。
Zotero 插件